2/27
10:34 pm
hrtx
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Neutral
Report
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/26
04:04 pm
hrtx
Heron Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Heron Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
03:11 pm
hrtx
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
08:34 am
hrtx
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results [Yahoo! Finance]
2/26
08:26 am
hrtx
Heron Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Heron Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
08:00 am
hrtx
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
High
Report
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
2/17
08:47 am
hrtx
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 [Yahoo! Finance]
Neutral
Report
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 [Yahoo! Finance]
2/17
08:30 am
hrtx
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Neutral
Report
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
1/25
07:42 am
hrtx
Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX) [Yahoo! Finance]
Neutral
Report
Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX) [Yahoo! Finance]
1/10
09:48 am
hrtx
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M [Yahoo! Finance]
Medium
Report
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M [Yahoo! Finance]
1/9
11:53 am
hrtx
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
1/9
09:29 am
hrtx
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Medium
Report
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
12/15
08:49 am
hrtx
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]
Medium
Report
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]
12/4
08:15 am
hrtx
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Medium
Report
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)